CV Sciences Sales Down 10 Percent
CV Sciences (OTC:CVSI), a consumer wellness company known for its hemp-derived CBD (cannabidiol) and plant-based products, reported first quarter results on May 14, 2025, for the period ended March 31. The release highlighted a 10.0% drop in GAAP revenue to $3.6 million compared to the prior year, steady gross margins of 46.0%, and ongoing cost controls. With no analyst estimates available, performance was measured against recent internal progress: revenue again trended down, but operating efficiency and continued product innovation offered some positives. The company returned to operating income (GAAP) of $11,000, driven by a one-time payroll tax reversal, though underlying profitability metrics, like adjusted EBITDA, remained negative.
CV Sciences develops, manufactures, and markets health-focused consumer products with a main emphasis on hemp-derived cannabidiol (CBD) supplements, topical solutions, and emerging plant-based food items. It operates in a highly regulated and evolving sector, serving both consumers and retailers through direct-to-consumer and wholesale channels.
Expansion into new categories has become central for the business, especially as core CBD revenues contract amidst rising regulation. The company’s recent focus includes driving operational efficiency, diversifying via new non-cannabinoid products, and leveraging acquisitions for cost savings and further innovation. Key success factors for its business include managing regulatory compliance, broadening distribution, and maintaining brand credibility in a crowded space.
Source Fool.com
